Donate to HEALEY ALS Platform Trial

The Sean M. Healey & AMG Center for ALS at Mass General is leading the first Platform Trial initiative for ALS. Traditionally, a trial evaluates only one drug at a time, and requires lengthy start-up and evaluation times. Platform trials, instead, allow multiple drugs to be tested at the same time. This approach cuts the time to finding effective treatments in half, decreases costs by a third, and greatly increases opportunities for people to receive new experimental therapies. It also helps accelerate the discovery of new biomarkers and learnings about the illness that could further accelerate therapy development. In 2020, the HEALEY ALS Platform Trial will test five new treatments (learn more here). Many more promising therapies are in the pipeline but need funding to move from the laboratory to individuals with ALS. With your support we can end this disease.

Mass General is a 501(c)3 non-profit organization and depends on the support of the public. All donations are tax-deductible to the full extent of the law. Our non-profit tax ID is 04-1564655.

For questions about your gift or giving via check, Donor Advised Fund, wire transfer or to donate stocks, bonds and mutual fund shares please see our Frequently Asked Questions or contact Emily Monteiro at emonteiro7@mgh.harvard.edu or (617) 643-7376.